Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colon and Rectal Cancer Clear all
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

NCT00055822
View directory record Official record
Conditions
Colorectal Cancer
Interventions
oblimersen sodium, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Not applicable Interventional

Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery

NCT00470353
View directory record Official record
Conditions
Colorectal Cancer
Interventions
calcium carbonate, cholecalciferol, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Dietary Supplement · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

NCT01640522
View directory record Official record
Conditions
Hepatocellular Carcinoma, Primary Liver Cancer, Bile Duct Cancer, Pancreatic Cancer, Gallbladder Cancer, Colorectal Carcinoma, Liver Metastases
Interventions
Collaborative Care, Enhanced usual Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 4 Interventional

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

NCT00216424
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine (Xeloda)
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2007 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer

NCT00296062
View directory record Official record
Conditions
Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, capecitabine, irinotecan hydrochloride, oxaliplatin
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2012 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

NCT03789162
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
44
States / cities
Phoenix, Arizona • Canoga Park, California • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

NCT01079780
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, ramucirumab, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
255
States / cities
Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 182 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer

NCT00016250
View directory record Official record
Conditions
Colorectal Cancer
Interventions
MKC-1
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma, Renal Cell Cancer Metastatic
Interventions
ZM008
Biological
Lead sponsor
Zumutor Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

Acupuncture Pilot Study for Cancer-related Cognitive Function

NCT04007770
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer, Gynecologic Cancer, Stage I Gynecologic Cancer, Stage II Gynecologic Cancer, Stage III Gynecologic Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

NSABP Patient Registry and Biospecimen Profiling Repository

NCT01793805
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
3,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
46
States / cities
Duarte, California • San Diego, California • Vallejo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

NCT00613080
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
119
States / cities
Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions
LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

NCT03475004
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Pembrolizumab, Bevacizumab, Binimetinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735
View directory record Official record
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

NCT05419011
View directory record Official record
Conditions
Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

NCT06270082
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Interventions
IK-595
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Duarte, California • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

NCT03031691
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
brontictuzumab, trifluridine/tipiracil
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374
View directory record Official record
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

NCT02788279
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Liver Metastases
Interventions
Tas-102, SIR-Sphere
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 5:16 AM EDT